Health Economics›Breast cancer›Metastatic disease first-line therapy premenopausal

Metastatic disease first-line therapy premenopausal

Breast cancer · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Goserelin, Letrozole, Ribociclib Variant #01	ER	R 23 809	28d	22.8 mo	58.7 mo	2	R 47 617 PFS proxy	3
Anastrozole, Goserelin, Ribociclib Variant #01	ER	R 23 597	28d	22.8 mo	58.7 mo	2	R 47 194 PFS proxy	3
Goserelin, Ribociclib, Tamoxifen Variant #01	ER	R 23 575	28d	23.8 mo	58.7 mo	2	R 47 149 PFS proxy	2
Goserelin and Tamoxifen Variant #01	ER	R 8 293	28d	13.0 mo	48.0 mo	2	R 16 587 PFS proxy	2
Goserelin and Letrozole Variant #01	ER	R 2 999	28d	13.0 mo	48.0 mo	2	R 5 997 PFS proxy	2
Anastrozole and Goserelin Variant #01	ER	R 2 787	28d	13.0 mo	48.0 mo	2	R 5 574 PFS proxy	2
Tamoxifen monotherapy Variant #01	ER	R 137	28d	6.8 mo	19.9 mo	26	R 3 553 PFS proxy	5

7 of 7 regimens shown